The Week Ahead: COS...
Health Care: Drugs
Geron Corporation (GERN: NASDAQ)
$1.12 0.00 | 0.00%
05/24/13 - 04:00 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with GERN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- Contributor22 Biopharma Stocks With Br...
- ContributorUnder-$10 Setting Up To Tra...
- ContributorStocks Under-$10 Moving Hig...
Latest GERN Headlines from TheStreet
- 8 Stocks Under $10 Soaring Higher 01.31.13 | 03:01 pm
- 5 Stocks Ready to Break Out 01.18.13 | 12:01 pm
- Stocks Slump as U.S. and Eurozone Uncertainties Fester 12.04.12 | 04:12 pm
- Stock Futures Point to Slightly Higher Wall Street Open 12.04.12 | 09:12 am
- Stocks to Watch: Oracle, Geron, Knight, Big Lots (Update 1) 12.04.12 | 07:12 am
- Morning Briefing: 10 Things You Should Know 12.04.12 | 06:12 am
- A Weak Open On Wall Street As China Stumbles 09.10.12 | 04:09 pm
- Geron's CEO Presents At Update On Imetelstat Clinical Development Program Conference (Transcript) 09.10.12 | 02:09 pm
- Geron Stung by Cancer Drug Blowup 09.10.12 | 08:09 am
- 5 Biotech Stocks Under $5 Blasting Off 08.16.12 | 03:08 pm
Press Releases for GERN
- Geron Initiates Phase 2 Trial Of GRN1005 In Brain Metastases From Breast Cancer - Business Wire 12.12.11 | 07:12 am
- Geron Presents Final Phase 1 Clinical Data On GRN1005 At AACR-NCI-EORTC - Business Wire 11.15.11 | 07:11 am
- Geron To Focus On Its Novel Cancer Programs - Business Wire 11.14.11 | 04:11 pm
- Geron Corporation Reports 2011 Third Quarter Financial Results And Events - Business Wire 11.03.11 | 04:11 pm
- Geron Announces Conference Call To Discuss Third Quarter Financial Results And Highlights - Business Wire 10.25.11 | 04:10 pm
- Geron Announces Presentation At ECTRIMS/ACTRIMS - Business Wire 10.25.11 | 07:10 am
- Geron Presents Clinical Data Update From GRNOPC1 Spinal Cord Injury Trial - Business Wire 10.20.11 | 07:10 am
- Geron Corporation Appoints John A. Scarlett As Chief Executive Officer And Director - Business Wire 09.29.11 | 05:09 pm
- Geron To Webcast Presentations At Upcoming Investor Conferences - Business Wire 09.12.11 | 07:09 am
- Geron Corporation Reports 2011 Second Quarter Financial Results And Events - Business Wire 07.28.11 | 04:07 pm
Partner Headlines for GERN
- Morning Market Losers - Benzinga 12.04.12 | 09:12 am
- Geron Posts Narrower Loss - Analyst Blog - Zacks 10.31.12 | 09:10 am
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- Geron Hit by Pipeline Setback - Analyst Blog - NASDAQ 09.11.12 | 09:09 pm
- Morning Market Losers - Benzinga 09.10.12 | 09:09 am
- UPDATE: Stifel Nicolaus Initiates Geron Corporation at Buy with $4 PT; Oncology Refocus Paying Off - Benzinga 08.30.12 | 12:08 pm
- Geron Posts In-Line Loss - Analyst Blog - Zacks 08.01.12 | 09:08 am
- Ford and 3 Stocks INITIATED at These Levels Today - Wall St. Cheat Sheet 06.28.12 | 03:06 am
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Neutral on Geron Corp. - Analyst Blog - Zacks 04.02.12 | 07:04 pm
